Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS

Key oral presentations highlight new safety, efficacy and workflow improvements data to optimize irrigation and support consistent procedural outcomes.YOKOHAMA, Japan, Nov. 3, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment1, today announced that new clinical and real-world data from its integrated-by-design VARIPULSE™ Platform in pulsed field ablation (PFA) procedures for atrial fibrillation (AF) will be presented at the Asia Pacific Heart Rhythm Society (AP ...